Semaglutide बनाम Tirzepatide: GLP-1 वर्ग विकल्प
BasicsDoctor Guide

Semaglutide बनाम Tirzepatide: GLP-1 वर्ग विकल्प

दोनों incretin family, अलग काम। Drug-class differences—खुद winner नहीं। upgrade, trial headlines, family anecdote—shared decision-making labs/comorbidities/budget। 2026 India cost, generic, RSSDI—molecule medical+financial conversation।

Short answer

Semaglutide GLP-1 only; tirzepatide GIP+GLP-1। Trials tirzepatide greater HbA1c/weight कुछ में, भारत में महँगा। Generic semaglutide access। Tolerance, CVD, budget—डॉक्टर चुनता, social media नहीं। Kesho बिना assessment recommend नहीं।

Key takeaways

  • •Semaglutide GLP-1 only; tirzepatide dual GIP+GLP-1—same incretin family different pharmacology।
  • •Head-to-head tirzepatide greater mean HbA1c/weight studied doses; individual response widely varies।
  • •Both similar GI titration; neither start/switch without medical supervision।
  • •India generic semaglutide access; tirzepatide 30–50% more limited generic 2026।
  • •Selection glycaemic goals, tolerance, CVD/kidney, route, monthly budget—not social media/pharmacy upselling।

Body में each medicine कैसे काम?

Semaglutide selective GLP-1 RA—GLP-1 mimic glucose-dependent insulin, glucagon suppress, gastric emptying slow, appetite reduce। Tirzepatide dual GIP+GLP-1 "twincretin"—GIP insulin sensitivity/fat metabolism beyond GLP-1। Both synthetic weekly subcutaneous diabetes/obesity approved। Neither insulin। Distinction prevents "GLP-1 shots" confusion—distinct pharmacology incretin umbrella। India both Schedule H CDSCO licensed pharmacy।

GIP

Glucose-dependent insulinotropic polypeptide—gut incretin insulin; tirzepatide GIP+GLP-1 both activate।

Major clinical trials क्या show?

SURMOUNT/SURPASS tirzepatide substantial weight/HbA1c obesity/T2D। STEP/SUSTAIN semaglutide impressive different magnitudes population/dose। SURMOUNT-2 head-to-head tirzepatide vs semaglutide 1 mg T2D greater mean HbA1c/weight studied doses। Trial populations ≠ every Indian—genetics, BMI, diet, adherence, thin-fat South Asia real-world। Indian registry accumulating। Trials drug-class efficacy; individual varies। Neither replaces lifestyle nor guarantees scale number। High-impact journals ≠ everyone newest molecule—access equity affordability Indian practice central। South Asian underrepresented subgroups—clinical judgement not automatic adoption।

Semaglutide vs tirzepatide overview

Weight loss/blood sugar compare?

Average tirzepatide somewhat greater mean weight higher doses vs semaglutide 2.4 mg obesity; greater HbA1c some diabetes head-to-head। "Average trial" single patient promise नहीं। Some robust semaglutide plateau tirzepatide; others one molecule only tolerate। Baseline HbA1c, diabetes duration, insulin, concurrent meds matter। RSSDI individualised targets—9.5%→7.8% affordable semaglutide clinically excellent though tirzepatide theoretically 7.2%। Loss beyond metabolic health not always necessary। Doctors efficacy vs cost side effects preference balance।

Typical trial outcomes (population averages, individual promises नहीं)

  • Outcome: Mean weight loss obesity — Semaglutide STEP/SUSTAIN: ~10–15% higher doses — Tirzepatide SURMOUNT/SURPASS: ~15–20% higher doses
  • Outcome: HbA1c T2D — Semaglutide: Often 1.0–1.5 points — Tirzepatide: Often 1.5–2.0+ some trials
  • Outcome: Time titrate — Both: Months gradual increases
  • Outcome: Lifestyle required — Both: Yes diet activity

Side effects/tolerability expect?

Both similar GI nausea diarrhoea constipation dose escalation prominent। Titration schedules differ rushing poor tolerance early stop। Gallbladder pancreatitis precautions both। Thyroid C-cell MTC/MEN2 class warnings। Injection-site uncommon weekly pens। Intolerance one may tolerate other—switch medical supervision not social media anecdotes। Oral semaglutide injection-averse; tirzepatide India injection only lacks। Smaller Indian meals fried avoid gradual dose both equally।

Cardiovascular/kidney factors choice influence?

Semaglutide extensive CVD outcome high-risk T2D atherosclerotic disease। Tirzepatide CVD data maturing। Both CKD stages glycaemic/weight incretin often preferred individual eGFR albuminuria dosing। Heart failure gastroparesis pancreatitis history limit/contraindicate either। Thyroid cancer family specialist review। High CVR affordability constraints semaglutide trial MACE benefits align may still start। Tirzepatide escalation semaglutide max tolerated dose targets unmet sometimes considered।

अंग्रेज़ी संस्करण →
Dr. Ananya Mehta

Medically reviewed

Dr. Ananya Mehta, MD, DM Endocrinology

Consultant Endocrinologist, India

This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.

Last medically reviewed: Jun 26, 2026

Editorial policy · Medical advisory team